ArticleMiddle East journal of digestive diseases2026
The Role of Comorbidities in Predicting 12-Month Survival in Patients with Liver Cirrhosis: A Study from Zahedan, Iran.
Article in Middle East journal of digestive diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Liver cirrhosis is a progressive disease characterized by the replacement of healthy liver tissue with scar tissue, leading to impaired liver function. Early diagnosis and management play a crucial role in improving patient outcomes. Comorbidities, including diabetes, hypertension, and dyslipidemia, are known to influence the prognosis of cirrhosis. This study aimed to assess the relationship between comorbid diseases and the 12-month survival of patients with liver cirrhosis in Zahedan, Iran. Methods: A retrospective cohort of patients with cirrhosis was followed for 12 months. Laboratory indices, including blood glucose, lipid profile, and blood pressure, were monitored. Survival analysis was performed to evaluate the impact of comorbidities on patient survival using statistical methods such as Kaplan-Meier and Cox regression analysis. Results: Abnormal blood glucose levels, high blood pressure, and dyslipidemia significantly reduced the 12-month survival of patients with cirrhosis. Despite treatment with lipid-lowering medications, lipid disturbances remained a key factor in the survival prognosis. Additionally, factors like body mass index and smoking habits were also identified as influential but often overlooked in clinical practice. Conclusion: This study underscores the importance of managing comorbidities in patients with cirrhosis to improve survival outcomes. The findings suggest that integrated care addressing both cirrhosis and its associated comorbidities can enhance patient prognosis. Further research is necessary to examine additional factors, such as physical activity, diet, and daily stress levels, which may also affect survival rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.